Skip to main content

Table 1 Patient demographic characteristics at entry. (P-values are from t-tests comparing those who took each drug to those who did not.)

From: A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people

  All Subjects Subjects with follow up Exposed to ZDV* Exposed to ddI†
N 33 23 19 7
Age in years: Mean (Range) 35.3 (23 – 51) 35.5 (23 – 51) 36.2 (23 – 51) (p = .27) 35.4 (25 – 51) (p = .97)
Male, N (%) 31 (94%) 21 (91%) 18 (95%) (p = .20) 6 (86%) (p = .53)
Race, N (%)  
White
Black
Hispanic
Asian
24 (73%)
3 (9%)
1 (3%)
5 (15%)
16(70%)
2 (9%)
1 (4%)
4 (17%)
14 (74%)
1 (5%)
0 (0%)
4 (21%) (p = .062)
6 (86%)
0 (0%)
1 (14%)
0 (0%) (p = .15)
CD4+ T-cells/ul Mean (Range) 483 (213 – 1130) 481 (213 – 960) 472 (213 – 960) (p = .64) 714 (444 – 960) (p < .0001)
Plasma HIV RNA‡ 1000 copies per/ml Mean (Range) 102 (0.1 – 670) (N = 31) 75 (0.1 – 505) (N = 22) 87 (0.1 – 505) (p = .69) 2.8 (0.1 – 8.0) (p = .0006)
Low Frequency PTA§in dB Mean (Range) 11 (0 – 40) (N = 32) 12 (0 – 40) 14 (1 – 40) (p = .41) 16 (0.5 – 40) (p = .40)
High Frequency PTA in dB Mean (Range) 20 (0.8 – 51) (N = 32) 22 (1.7 – 51) 22 (2 – 51) (p = .98) 23 (3 – 50) (p = .64)
  1. *ZDV = zidovudine, †ddI = didanosine, ‡RNA = ribonucleic acid, §PTA = pure tone average